Skip to main content

Advertisement

SpringerLink
Log in

Preventing HIV in injection drug users: Choosing the best mix of interventions for the population

  • Original Articles: Various Topics
  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

Injection drug users (IDUs) transmit the human immunodeficiency virus (HIV) via both needle sharing and sex. This analysis explores the effects of population risk behaviors, intervention effectiveness, intervention costs, and budget and capacity constraints when allocating funds between two prevention programs to maximize effectiveness. The two interventions, methadone maintenance and street outreach, address different types of risk behavior. We developed a model of the spread of HIV and dwided IDUs into susceptible (uninfected) persons and infective persons and separately portrayed sex and injection risk. We simulated the epidemic in San Francisco, California, and New York City for periods from the mid-1980s to the mid-1990s and incorporated the behavioral effects of the two interventions. We used the simulation to find the allocation of a fixed budget to the two interventions that averted the greatest number of infections in the IDUs and their noninjecting sex partners. We assumed that interventions have increasing marginal costs. In the epidemic scenarios, our analysis found that the best allocation nearly always involves spending as much as possible on street outreach. This result is largely insensitive to variations in epidemic scenario, intervention efficacy, and cost. However, the absolute and relative benefits of the best allocation varied. In mid-1990s San Francisco, maximizing spending on outreach averted 3.5% of total HIV infections expected and 10 times the 0.3% from maximizing spending on treatment. In late 1980s New York City, the difference is five-fold (2.6% vs. 0.44%, respectively). Our analyses suggest that, even though prevention works better in higher risk scenarios, the choice of intervention mix is more important in the lower risk scenarios. Models and analyses such as those presented heve may help decision makers adapt individual prevention programs to their own communities and to reallocate resources among programs to reflect the evolution of their own epidemics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Anderson JE, Wilson RW, Barker P, Doll L, Jones TS, Holtgrave D. Prevalence of sexual and drug-related HIV risk behaviors in the US adult population: results of the 1996 national household survey on drug abuse. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:148–156.

    CAS  Google Scholar 

  2. Murrill CS, Prevots DR, Miller MS, Linley LA, Royalty JE, Gwinn M. Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health. 2001;78:152–161.

    CAS  PubMed  Google Scholar 

  3. Dinwiddie SH, Cottler L, Compton W, Abdallah AB. Psychopathology and HIV risk behaviors among injection drug users in and out of treatment. Drug Alcohol Depend. 1996;43:1–11.

    Article  CAS  PubMed  Google Scholar 

  4. Camacho LM, Bartholomew NG, Joe GW, Simpson DD. Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up. Drug Alcohol Depend. 1997;47:11–18.

    Article  CAS  PubMed  Google Scholar 

  5. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–654.

    Article  CAS  PubMed  Google Scholar 

  6. 2001 San Francisco HIV prevention plan. San Francisco, CA: HIV Prevention Planning Council and San Francisco Department of Public Health, AIDS Office; 2001. Available at: http://www.dph.sf.ca.us/HIVPrevPlan/page2.htm. Accessed October 11, 2002.

  7. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999;13:1807–1818.

    Article  CAS  PubMed  Google Scholar 

  8. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health. 1996;86:1442–1445.

    Article  CAS  PubMed  Google Scholar 

  9. Gibson DR, McCusker J, Chesney M. Effectiveness of psychosocial interventions in preventing HIV risk behavior in injecting drug users AIDS. 1998;12:919–929.

    Article  CAS  PubMed  Google Scholar 

  10. Carlson RG, Wang J, Siegal HA, Falck RS. A preliminary evaluation of a modified needle-cleaning intervention using bleach among injection drug users. AIDS Educ Prev. 1998;10:523–532.

    CAS  PubMed  Google Scholar 

  11. McCoy HV, McCoy CB, Lai S. Effectiveness of HIV interventions among women drug users. Women Health. 1998;27:49–66.

    Article  CAS  PubMed  Google Scholar 

  12. Kotranski L, Semaan S, Collier K, Lauby J, Halbert J, Feighan K. Effectiveness of an HIV risk reduction counseling intervention for out-of-treatment drug users. AIDS Educ Prev. 1998;10:19–33.

    CAS  PubMed  Google Scholar 

  13. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:282–289.

    CAS  PubMed  Google Scholar 

  14. Sorensen JL, London J, Heitzmann C, et al. Psychoeducational group approach: HIV risk reduction in drug users. AIDS Educ Prev. 1994;6:95–112.

    CAS  PubMed  Google Scholar 

  15. Rietmeijer CA, Kane MS, Simons PZ, et al. Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program. AIDS. 1996;10:291–298.

    Article  CAS  PubMed  Google Scholar 

  16. Stevens SJ, Estrada AL, Estrada BD. HIV sex and drug risk behavior and behavior change in a national sample of injection drug and crack cocaine using women. Women Health. 1998;27:25–48.

    Article  CAS  PubMed  Google Scholar 

  17. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA. 1994;271:115–120.

    Article  CAS  PubMed  Google Scholar 

  18. Kaplan EH. Economic analysis of needle exchange. AIDS. 1995;9:1113–1119.

    Article  CAS  PubMed  Google Scholar 

  19. Longshore D, Annon J, Anglin MD. Long-term trends in self-reported HIV risk behavior: injection drug users in Los Angeles, 1987 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:64–72.

    CAS  PubMed  Google Scholar 

  20. Latkin CA, Vlahov D, Anthony JC, Cohn S, Mandell W, Nelson KE. Needle-cleaning practices among intravenous drug users who share injection equipment in Baltimore, Maryland. Int J Addict. 1992;27:717–725.

    CAS  PubMed  Google Scholar 

  21. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention, and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 1996;42:11–20.

    Article  CAS  PubMed  Google Scholar 

  22. Schutz CG, Vlahov D, Anthony JC, Graham NM: Comparison of self-reported injection frequencies for past 30 days and 6 months among intravenous drug users. J Clin Epidemiol. 1994;47:191–195.

    Article  CAS  PubMed  Google Scholar 

  23. Singer M, Himmelgreen D, Dushay R, Weeks MR. Variation in drug injection frequency among out-of-treatment drug users in a national sample. Am J Drug Alcohol Abuse. 1998;24:321–341.

    Article  CAS  PubMed  Google Scholar 

  24. Des Jarlais DC, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990–1997. Am J Public Health. 2000;90:1112–1116.

    Article  PubMed  Google Scholar 

  25. Watters JK. Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986–1992. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:1276–1281.

    CAS  Google Scholar 

  26. Longshore D, Anglin MD, Annon K, Hsieh S. Trends in self-reported HIV risk behavior: injection drug users in Los Angeles. J Acquir Immune Defic Syndr Hum Retrovirol. 1993;6:82–90.

    CAS  Google Scholar 

  27. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357:1397–1401.

    Article  CAS  PubMed  Google Scholar 

  28. Valdiserri RO, Aultman TV, Curran JW. Community planning: a national strategy to improve HIV prevention programs. J Community Health. 1995;20:87–100.

    Article  CAS  PubMed  Google Scholar 

  29. Dearing JW, Larson RS, Randall LM, Pope RS. Local reinvention of the CDC HIV prevention community planning initiative. J Community Health. 1998;23:113–126.

    Article  CAS  PubMed  Google Scholar 

  30. Ruiz MS, Gable AR, Kaplan EH, Stoto MA, Fineberg HV, Trussel J, eds. No Time to Lose: Getting More From HIV Prevention. Institute of Medicine. Committee on HIV Prevention Strategies in the United States. Washington, DC: National Academy Press; 2001.

    Google Scholar 

  31. Rauner MS, Brandeau ML. AIDS policy modeling for the 21st century: an overview of key issues Health Care Manag Sci. 2001;4:165–180.

    Article  CAS  PubMed  Google Scholar 

  32. Richter A, Brandeau ML, Owens DK. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Med Decis Making. 1999;19:167–179.

    Article  CAS  PubMed  Google Scholar 

  33. Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. Med Decis Making. 2001;21:391–408.

    Article  CAS  PubMed  Google Scholar 

  34. Kahn JG, Washington AE, Showstack JA, et al. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report prepared for the Centers for Disease Control. Institute for Health Policy Studies, University of California, San Francisco, 1992.

    Google Scholar 

  35. Wilson AR, Kahn JG. Preventing HIV in IDUs: exploring, the trade-offs between interventions. Socio-Econ Plann Sci. In press.

  36. Lewis DK, Watters JK. Sexual risk behavior among heterosexual intravenous drug users: ethnic and gender variations. AIDS. 1994;5:77–83.

    Article  Google Scholar 

  37. Cohen JB, Hauer LB, Wofsy CB. Women and IV drugs: parenteral and heterosexual transmission of human immunodeficiency virus. J Drug Issues. 1989;19:39–56.

    Google Scholar 

  38. Friedland GH, Klein RS. Transmission of the human immunodeficiency virus. N Engl J Med. 1987;317:1125–1135.

    Article  CAS  PubMed  Google Scholar 

  39. Friedman SR, Des Jarlais DC, Neaigus A, et al. AIDS and the new drug injector. Nature. 1989;339:333–334.

    Article  CAS  PubMed  Google Scholar 

  40. Des Jarlais DC, Wish E, Friedman SR, et al. Intravenous drug use and the heterosexual transmission of the human immunodeficiency virus. Current trends in New York City. N Y State J Med. 1987;87:283–286.

    PubMed  Google Scholar 

  41. Kaplan EH. Modeling HIV infectivity: must sex acts be counted? J Acquir Immune Defic Syndr Hum Retrovirol. 1990;3:55–61.

    CAS  Google Scholar 

  42. Haverkos HW, Battjes RJ. Female-to-male transmission of HIV [letter]. JAMA. 1992; 268:1855–1856.

    Article  CAS  PubMed  Google Scholar 

  43. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation poop. Ann Intern Med. 1990;113:740–746.

    CAS  PubMed  Google Scholar 

  44. Kahn JG. Are NEPs cost-effective in preventing HIV infection? In: Lurie P, Reingold AL, ed. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. 1993. Available at http://www.caps.ucsf.edu/publications/needlereport. html. Accessed October 11, 2002.

  45. Watters JK, Jones TS, Shapshak P, et al. Household bleach as disinfectant for use by injecting drug users. Lancet. 1993;342:742–743.

    Article  CAS  PubMed  Google Scholar 

  46. Gleghorn AA, Doherty MC, Vlahov D, Celentano DD, Jones TS. Inadequate bleach contact times during syringe cleaning among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;7:767–772.

    CAS  Google Scholar 

  47. Vlahov D, Munoz A, Celentano DD, et al. HIV seroconversion and disinfection of injection equipment among intravenous drug users, Baltimore, Maryland. Epidemiology. 1991;2:444–446.

    Article  CAS  PubMed  Google Scholar 

  48. Vaillant GE. The natural history of narcotic drug addiction. Semin Psychiatry. 1970;2:486–498.

    CAS  PubMed  Google Scholar 

  49. Hser Y, Anglin MD, Powers KI. A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry. 1993;50:577–584.

    CAS  PubMed  Google Scholar 

  50. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I. AIDS. 1994;8:911–921.

    Google Scholar 

  51. Hahn RA, Onorato IM, Jones TS, Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA. 1989;261:2677–2684.

    Article  CAS  PubMed  Google Scholar 

  52. Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS Behav. 1999;3:3–12.

    Article  Google Scholar 

  53. Watters JK, Bluthenthal RN, Kral AH. HIV seroprevalence in injection drug users. JAMA. 1995;273:1178.

    Article  CAS  PubMed  Google Scholar 

  54. Bluthenthal RN, Lorvick J, Kral AH, Erringer EA, Kahn JG. Collateral damage in the war on drugs: HIV risk behaviors among injection drug users. Int J Drug Policy. 1999; 10:25–38.

    Article  Google Scholar 

  55. Des Jarlais D, Perlis T, Friedman S, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998;88:1801–1806.

    Article  PubMed  Google Scholar 

  56. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic: injecting drug users in New York City, 1984–1992. JAMA. 1994;271:121–127.

    Article  PubMed  Google Scholar 

  57. Abdul-Quader AS, Friedman SR, Des Jarlais DC, Marmor MM, Maslansky M, Bartelme S. Methadone maintenance and behavior by intravenous drug users that can transmit HIV. Contemp Drug Probl. 1987;3:425–434.

    Google Scholar 

  58. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44:1303–1312.

    Article  CAS  PubMed  Google Scholar 

  59. Battjes RJ, Pickens RW, Brown LSJ. HIV infection and AIDS risk behaviors among injecting drug users entering methadone treatment: an update. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:90–96.

    CAS  PubMed  Google Scholar 

  60. Moss AR. HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS. 1994;8:223–231.

    Article  CAS  PubMed  Google Scholar 

  61. Moss AR, Bacchetti P, Osmond D, Meakin R, Keffelew A, Gorter R. Seroconversion for HIV in intravenous drug users in San Francisco. Paper presented at: Fifth International Conference on AIDS; June 4–9, 1989. Montreal, Canada.

  62. HIV prevalence estimates and AIDS case projections for the United States: report based upon a workshop. MMWR Morb Mortal Wkly Rep. 1990;39:1–18.

    Google Scholar 

  63. Ball JC, Lange WR, Myers PC, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214–226.

    Article  CAS  PubMed  Google Scholar 

  64. Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD. Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug Alcohol Depend. 1996;41:1–7.

    Article  CAS  PubMed  Google Scholar 

  65. Ball J, Corty E, Bond H, Myers C, Tommasello A. The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res Monogr. 19988;81:224–230.

    Google Scholar 

  66. Sisk JE, Hatziandreu EJ, Hughes R, et al. The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection. Office of Technology Assessment, Series on AIDS-Related Issues. 1990. Background paper 6. Available at http://govinfo. library.unt.edu/ota/Ota-2/DATA/1990/9041.PDF. Accessed October 11, 2002.

  67. Iguchi MY, Bux DA, Platt JJ, et al. Reduction in high-risk behaviors in IDUs at 6-month follow-up. Poster presentation at: Third Annual NADR Conference; October 29–31, 1991. Rockville, MD.

  68. Watters JK, Downing M, Case P, Lorvick J, Cheng Y, Fergusson B. AIDS prevention for intravenous drug users in the community: street-based education and risk behavior. Am J Community Psychol. 1990;18:587–596.

    Article  CAS  PubMed  Google Scholar 

  69. Booth RE, Kwiatkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoactive Drugs. 1998;30:269–278.

    CAS  PubMed  Google Scholar 

  70. Des Jarlais DC, Friedmann P, Hagan H, Friedman SR. The protective effect of AIDS-related behavioral change among injection drug users: a cross-national study. Am J Public Health. 1996;86:1780–1785.

    Article  PubMed  Google Scholar 

  71. Norton EC, Martin RF, Wechsberg WM. Threshold analysis of AIDS outreach and intervention. In: Holtgrave DR, ed. Handbook of Economic Evaluation of HIV Prevention Programs. New York, NY: Plenum Press; 1998:195–210.

    Google Scholar 

  72. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health. 2000;90:1100–1111.

    Article  CAS  PubMed  Google Scholar 

  73. Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV prevention: A cost-effectiveness analysis. Manag Sci. 2000;46:1013–1031.

    Article  Google Scholar 

  74. Pollack H. Methadone treatment as HIV prevention: cost-effectiveness analysis. In: Kaplan EH, Brookmeyer R, eds. Quantitative Evaluation of HIV Prevention Programs. New Haven, CT: Yale University Press; 2002:118–142.

    Google Scholar 

  75. Gerstein DR, Johnson RA, Harwood HJ, et al. California Department of Alcohol and Drug Programs. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). 1994. Available at: http://www.adp.cahwnet.gov/pdf/caldata. pdf. Accessed October 11, 2002.

Download references

Author information

Authors and Affiliations

  1. the Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Twin Cities, Minnesota, USA

    Amy R. Wilson

  2. the Institute for Health Policy Studies and AIDS Research Institute, University of California, San Francisco

    James G. Kahn

Authors
  1. Amy R. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James G. Kahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy R. Wilson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilson, A.R., Kahn, J.G. Preventing HIV in injection drug users: Choosing the best mix of interventions for the population. J Urban Health 80, 465–481 (2003). https://doi.org/10.1093/jurban/jtg046

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1093/jurban/jtg046

Keywords

Search

Navigation